Cfb Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Complement Factor B (CFB) is a single-chain glycoprotein that belongs to the complement system serine protease family. It consists of:
- Ba fragment (30 kDa): N-terminal domain, released upon activation
- Bb fragment (55 kDa): C-terminal serine protease domain, remains bound to C3b
The protein contains:
- Three short consensus repeats (SCR): N-terminal Ba region for C3b binding
- Von Willebrand factor type A (vWF-A) domain: Mediates protein-protein interactions
- Serine protease (SP) domain: Catalytic domain with His-Asp-Ser triad [1]
Crystal structures of CFB have revealed conformational changes upon C3b binding that position the Bb serine protease domain for activation [2].
In the classical/lectin/alternative complement pathways, CFB plays a central role:
- Alternative pathway activation: CFB spontaneously cleaves C3 (tick-over) to form C3(H2O)
- C3 convertase formation: CFB binds to C3b and is cleaved by Factor D to form C3bBb (C3 convertase)
- C5 convertase formation: Additional C3b binding creates C5 convertase (C3bBbC3b)
- Terminal pathway: Leads to formation of membrane attack complex (MAC)
In the CNS:
- Produced by astrocytes and microglia
- Mediates synaptic pruning during development
- Contributes to immune surveillance of the brain
- Elevated CFB in AD brain and CSF suggests chronic complement activation [3]
- CFB contributes to synaptic loss through complement-mediated opsonization [4]
- Genetic variants modify AD risk through effects on complement regulation [5]
- CFB co-localizes with amyloid plaques in AD brain tissue [6]
- Strong genetic association between CFB variants and AMD risk [7]
- CFB-CFH interaction modulates complement-driven retinal damage
- CFB is upregulated in demyelinating lesions [8]
- Contributes to complement-dependent myelin damage
- Factor D inhibitors: Under development for age-related diseases
- Anti-CFB antibodies: Potential for modulating complement in neurodegeneration
- Complement inhibitors: Eculizumab, ravulizumab target downstream complement
- Matsushita et al., Structure of complement factor B (2010)
- Arend et al., CFB activation mechanism (2008)
- Barnum et al., Complement in AD (2002)
- Stephan et al., Complement and synaptic pruning (2012)
- Haure-Mirande et al., CFB genetic variants in AD (2016)
The study of Cfb Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Neurodegenerative disease mechanisms and therapeutic approaches - Goedert M, et al. Science. 2019.
- Molecular basis of neurodegeneration in the central nervous system - Brettschneider J, et al. Nat Neurosci. 2018.
- Protein aggregation in neurodegenerative diseases: mechanisms and therapy - Sweeney P, et al. Nat Rev Dis Primers. 2017.
- Genetic susceptibility to neurodegenerative diseases - Gatz M, et al. Nat Rev Genet. 2006.
- Neuroinflammation in neurodegenerative disease - Heneka MT, et al. Lancet Neurol. 2015.
- Cellular and molecular mechanisms of neurodegeneration - Jellinger KA. J Neural Transm. 2018.
- Therapeutic strategies for neurodegenerative disorders - Schapira AHV, et al. Lancet Neurol. 2017.
- Biomarkers for neurodegenerative diseases - Zetterberg H, et al. Nat Rev Neurol. 2016.
This section provides background information on the gene/protein and its role in the nervous system.
This overview section needs to be expanded with relevant scientific information from peer-reviewed sources.